The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
With rich countries like the US finding it hard to fund gene therapies, it is worth asking whether these projects will ever reach patients in developing countries. And if…